Cilengitide and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Lung Cancer

Inclusion Criteria: DISEASE CHARACTERISTICS: * Histologically confirmed lung cancer (small cell or non-small cell lung cancer) * Patient must be eligible for whole-brain radiotherapy * Presence of brain metastasis (single or multiple, synchronous or metachronous) from lung cancer not amenable to surgery or radiosurgery (presence of metastases at any other site is allowed) * No leptomeningeal metastasis or known subarachnoid spread of tumor PATIENT CHARACTERISTICS: * ECOG performance status (PS) 0-1 (ECOG PS 2 allowed if due to the presence of cerebral metastases and not due to a high peripheral-tumor load or other reasons) * Life expectancy ≥ 3 months * Adequate hematologic function * Total bilirubin \< 1.5 times upper limit of normal (ULN) * AST, ALT, and alkaline phosphatase \< 2.5 times ULN * Creatinine clearance \> 60 mL/min * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 6 months after completion of study treatment * No history of acute or chronic renal disease * No other malignancies treated within the past 5 years, except adequately treated carcinoma in situ of the cervix or basal cell carcinoma of the skin * No uncontrolled hypertension * No history of coagulation disorder associated with bleeding or recurrent thrombotic events * No peptic ulcer disease within the past 6 months * No congestive heart failure, high risk for uncontrolled arrhythmia, or history of clinically significant coronary he…